Condensed Consolidated Balance Sheets (USD $) In Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2011	Dec. 31, 2010
Current assets
Cash and cash equivalents	$ 202,961	$ 235,136
Receivables, less allowance for doubtful accounts of $5,854 at June 30, 2011 and $5,322 at December 31, 2010	270,234	213,553
Inventories - net	282,381	196,546
Other current assets	58,429	47,523
Total current assets	814,005	692,758
Property, plant and equipment - net	231,538	188,562
Goodwill	1,450,988	1,207,001	[1]
Intangible assets - net	406,340	281,392
Other noncurrent assets	20,449	11,982
Total assets	2,923,320	2,381,695
Current liabilities
Trade accounts payable	128,117	104,055
Accrued expenses	122,894	117,879
Current portion of long term debt and short term borrowings	85,020	119,445
Dividends payable	14,095	12,289
Total current liabilities	350,126	353,668
Long-term borrowings	793,117	408,450
Deferred income taxes	169,810	148,534
Other noncurrent liabilities	98,617	95,383
Total liabilities	1,411,670	1,006,035
Commitments and contingencies
Preferred stock:
Authorized: 5,000,000 shares, $.01 per share par value; Issued: None
Common stock:
Authorized: 150,000,000 shares, $.01 per share par value Issued: 85,751,231 shares at June 30, 2011 and 84,636,668 shares at December 31, 2010	858	846
Additional paid-in capital	478,173	441,271
Retained earnings	1,075,006	1,005,040
Treasury stock at cost: 2,729,127 shares at June 30, 2011 and 2,566,985 shares at December 31, 2010	(64,556)	(58,788)
Accumulated other comprehensive income (loss)	22,169	(12,709)
Total shareholders' equity	1,511,650	1,375,660
Total liabilities and shareholders' equity	$ 2,923,320	$ 2,381,695

[1] Revised to reflect the movement of the Pharma group from the Fluid & Metering Technologies Segment to the Health & Science Technologies Segment.